KFDA Ordered to change Labelling for Echinace drugs.

Published: 2001-12-05 06:56:00

Updated: 2001-12-05 06:56:00

The KFDA ordered to change its labelling for Echinacea extract preparations covering indications as a supplemental prevention and treatment of the common cold and other respiratory tract disorders and an immunity enhancement into a supplemental therapy for recurrent respiratory infections.

R...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK